Nordic Nanovector ASA: Annual General Meeting Held

OSLO, Norway, April 25, 2019 /PRNewswire/ -- The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway.

All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 4 April 2019.

The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com.

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44-7561-431-762

Email: [email protected]  

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--annual-general-meeting-held,c2797177

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-annual-general-meeting-held-300838386.html

SOURCE Nordic Nanovector